Why Did Bayer Still Pay $63 Billion for Monsanto?

Why did Bayer pay $63 billion for Monsanto when the Roundup lawsuits were already public? Bayer did not miss the risk. It may have measured the wrong part of it. The deal promised seeds, genetic traits, crop protection, data, and a stronger position in a rapidly consolidating agricultural industry. But 64 days after the acquisition closed, the first Roundup trial verdict changed the shape of that risk. What looked like a legal question with a defensible final answer became years of claims, jury decisions, settlements, reserves, and uncertainty. This documentary reconstructs the strategic logic behind the acquisition, the regulatory disagreement around glyphosate, the structure of the merger agreement, the $9 billion divestiture required by U.S. regulators, the Roundup litigation, and the 2026 U.S. Supreme Court decision in Monsanto v. Durnell. The central question is not whether Bayer saw the danger. It is whether the company measured the right version of it. This video examines corporate decision-making and litigation risk. It does not provide medical or legal advice and does not independently determine the scientific safety of glyphosate. Selected public sources: Bayer — completion of the Monsanto acquisition: https://www.bayer.com/media/en-us/bay... U.S. Department of Justice — required divestitures: https://www.justice.gov/archives/opa/... Bayer — 2020 legacy Monsanto litigation agreements: https://www.bayer.com/media/bayer-ann... U.S. Supreme Court — Monsanto Co. v. Durnell: https://www.supremecourt.gov/opinions... #Bayer #Monsanto #Roundup TAGS Bayer, Monsanto, Roundup, glyphosate, Bayer Monsanto merger, Monsanto acquisition, Roundup lawsuits, corporate strategy, business documentary, mergers and acquisitions, litigation risk, business case study, corporate decision making, The Hidden Decision